MXPA03009720A - USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. - Google Patents

USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.

Info

Publication number
MXPA03009720A
MXPA03009720A MXPA03009720A MXPA03009720A MXPA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
MXPA03009720A
Other languages
English (en)
Spanish (es)
Inventor
Anthony P D W Ford
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03009720A publication Critical patent/MXPA03009720A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03009720A 2001-04-23 2002-02-02 USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. MXPA03009720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
PCT/EP2002/001085 WO2002085458A2 (en) 2001-04-23 2002-02-02 Use of nk-1 receptor antagonists against benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
MXPA03009720A true MXPA03009720A (es) 2004-01-29

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009720A MXPA03009720A (es) 2001-04-23 2002-02-02 USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.

Country Status (17)

Country Link
US (1) US20030004157A1 (enExample)
EP (1) EP1385577B1 (enExample)
JP (1) JP4146730B2 (enExample)
KR (1) KR100599134B1 (enExample)
CN (1) CN100398106C (enExample)
AR (1) AR035935A1 (enExample)
AT (1) ATE323531T1 (enExample)
AU (1) AU2002250876B2 (enExample)
BR (1) BR0209151A (enExample)
CA (1) CA2444395C (enExample)
DE (1) DE60210760T2 (enExample)
DK (1) DK1385577T3 (enExample)
ES (1) ES2261657T3 (enExample)
MX (1) MXPA03009720A (enExample)
PT (1) PT1385577E (enExample)
WO (1) WO2002085458A2 (enExample)
ZA (1) ZA200308110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
JP5026702B2 (ja) * 2003-01-31 2012-09-19 エフ.ホフマン−ラ ロシュ アーゲー 2−(3,5−ビス−トリフルオロメチル−フェニル)−N−[6−(1,1−ジオキソ−1λ6−チオモルホリン−4−イル)−4−(4−フルオロ−2−メチル−フェニル)−ピリジン−3−イル]−N−メチル−イソブチルアミドの新規な結晶変形
CN1852712B (zh) * 2003-07-03 2010-06-09 弗·哈夫曼-拉罗切有限公司 用于治疗精神分裂症的双重nk1/nk3拮抗剂
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
WO2006002860A1 (en) 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
EP2395002B1 (en) 2005-11-08 2014-06-18 Vertex Pharmaceuticals Inc. Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
UA102534C2 (xx) 2007-12-07 2013-07-25 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
LT2639223T (lt) 2007-12-07 2017-06-26 Vertex Pharmaceuticals Incorporated Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
NZ595723A (en) 2009-03-17 2012-10-26 Daiichi Sankyo Co Ltd Amide derivative
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
CN102917692A (zh) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
PL3067349T3 (pl) 2013-11-08 2018-06-29 Kissei Pharmaceutical Co., Ltd. Pochodna karboksymetylopiperydyny
BR112016010403A2 (pt) 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US11801244B2 (en) * 2018-02-02 2023-10-31 Eustralis Pharmaceuticals Limited Parenteral formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
WO1999007677A1 (en) * 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
PL338456A1 (en) * 1997-08-06 2000-11-06 Lilly Co Eli 2-acylaminopropanoamines as antagonists of the tachykinin receptor
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
IL153834A0 (en) * 2000-07-14 2003-07-31 Hoffmann La Roche N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
BR0209151A (pt) 2004-07-13
WO2002085458A2 (en) 2002-10-31
JP4146730B2 (ja) 2008-09-10
PT1385577E (pt) 2006-08-31
ZA200308110B (en) 2005-03-30
WO2002085458A3 (en) 2003-10-30
CN100398106C (zh) 2008-07-02
DE60210760D1 (de) 2006-05-24
AU2002250876B2 (en) 2005-03-03
KR100599134B1 (ko) 2006-07-12
JP2004529931A (ja) 2004-09-30
DK1385577T3 (da) 2006-08-21
EP1385577B1 (en) 2006-04-19
CN1503684A (zh) 2004-06-09
ES2261657T3 (es) 2006-11-16
ATE323531T1 (de) 2006-05-15
EP1385577A2 (en) 2004-02-04
DE60210760T2 (de) 2006-11-23
AR035935A1 (es) 2004-07-28
KR20040007503A (ko) 2004-01-24
CA2444395A1 (en) 2002-10-31
US20030004157A1 (en) 2003-01-02
CA2444395C (en) 2010-12-21

Similar Documents

Publication Publication Date Title
MXPA03009720A (es) USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
MXPA03006121A (es) Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis.
ZA200401214B (en) Synthesis of poly-alpha olefin and use thereof.
ITMI20002076A0 (it) Procedimento ed apparecchiatura per il controllo della miscelazione di bevande.
MXPA03000738A (es) Antagonistas de grelina.
IL162266A (en) Substituted 2-thio-3,5-dicyano-4- phenyl-6-aminopyridines and the use of the same
AU2002367424A1 (en) Androgen receptor antagonists
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
IL158701A0 (en) Novel use of nk3 receptor antagonist
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
AU8177801A (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
MXPA03003892A (es) Antagonistas del receptor bombesin.
MXPA03004414A (es) Natagonistas del receptor bombesin.
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
PL370367A1 (en) Ccr-3 receptor antagonists v
IL137953A0 (en) Phthalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia
GB0301016D0 (en) Treatment of benign prostatic hyperplasia
MXPA03006970A (es) Nuevo uso de iloperidona.
ZA200401146B (en) Agonists and antagonists of 5HT3-like receptor of invertebrates as pesticides.
GB2418985B (en) Protein markers for human benign prostatic hyperplasia(BPH)
DK1056720T3 (da) Phtalimido-arylpiperaziner som alfa-1A-receptorantagonister, der er nyttige til behandling af godartet prostatahyperplasi
MXPA03004249A (es) Nuevos usos de combinaciones selectivas antagonistas del receptor de dopamina d2 y agonistas del receptor de 5-ht1a.
AU2002348270A8 (en) Fire hydrant lock
GB2382281B (en) Authentication of network users

Legal Events

Date Code Title Description
FG Grant or registration